Navigation Links
Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
Date:6/18/2012

WASHINGTON, June 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that Michael Cola has joined Vanda's Board of Directors. Mr. Cola will also serve as a member of the Audit Committee of the Board replacing Howard Pien, who will continue to serve as the Chairman of the Board and as a member of each of the Compensation Committee and the Nominating/Corporate Governance Committee of the Board.  In connection with Mr. Cola's election, the Board has increased the number of directors to seven.

"I would like to personally welcome Mike to our Board," said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer of Vanda. "We are very fortunate to have someone with his breadth of pharmaceutical industry and leadership experience on our Board as we continue to develop and commercialize our clinical assets."

Mr. Cola served as President of Shire plc's Specialty Pharmaceuticals business from 2007 until April 2012. Mr. Cola joined Shire in July 2005 as Executive Vice President for Global Therapeutic Business Units and Portfolio Management prior to being named President of the Specialty Pharmaceuticals business. Prior to joining Shire, Mr. Cola spent more than five years at Safeguard Scientifics, where he served as President of the Life Sciences Group. As part of his role with Safeguard Scientifics, Cola served as Chairman and CEO of Clarient, a cancer diagnostics company, and Chairman of Laureate Pharma, a full service contract manufacturing organization serving research based biologics companies.  Prior to joining Safeguard Scientifics, Mr. Cola held progressively senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and later with AstraZeneca.  Mr. Cola currently serves on the Board of Directors of NuPathe Pharmaceuticals, is a member of the Board of Trustees of Ursinus College, and a member of the Board of Directors of Pennsylvania Bio, the statewide association representing the biosciences community.  Mr. Cola received his Bachelor of Arts degree in biology and physics from Ursinus College and his Master of Science degree in biomedical science from Drexel University.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
cristina.murphy@vandapharma.com

 

 


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
2. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
3. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
4. American Society of Hematology joins European Hematology Association, Patient Groups in Issuing International Call to Action to Alleviate Drug Shortages
5. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
6. Anthony Creed Joins DDSTUDIO As GM, Experience Design
7. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
8. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
9. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
10. David F. Harty Joins Systech International as Vice President
11. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016  Breckenridge Pharmaceutical, Inc. announced today that ... with development and manufacturing partner Gland Pharma Limited ... of this agreement, Breckenridge will market and distribute ... the United States . The deal includes ... products cover a wide range of indications.  This ...
(Date:12/5/2016)... Oregon and PUNE, India , ... new report by Allied Market Research, titled, "Global Cancer Biomarkers ... global revenue of cancer biomarkers market is projected to reach ... a CAGR of 13.3% from 2016 to 2022. Omic technologies ... in 2015 and is expected to maintain its dominance during ...
(Date:12/5/2016)... Dec. 5, 2016  Recently Zymo Research announced ... predictor, known as Horvath,s Clock. Based on this ... analysis service to academic and biopharma scientific researchers ... sample, other than sperm. The service ... biological age versus chronological age following drug treatments ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The ... formally announce its Not a Moment to Lose fundraising campaign. As the V ... dedicated to declaring victory over cancer. The campaign aims to raise $200 million ...
(Date:12/6/2016)... Pittsburgh, PA (PRWEB) , ... December 06, 2016 ... ... particle identification and characterization laboratories, is now offering HIAC particle counting and sizing ... available immediately. , Gateway Analytical instituted the new service as a response to ...
(Date:12/6/2016)... Switzerland (PRWEB) , ... December 06, 2016 , ... ... a one-stop portal for all the knowledge resources, including white papers, guides, ... certificates, and more. , To access more than 9,000 documents, webinars and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... ... ... Keeping Gift Season Safe, In a season stacked with gift-giving opportunities, it's ... recipients. This is the idea behind Safe Toys and Gifts Month, which sets aside ... good gifts for children. For companies that produce goods that fall into this category, ...
Breaking Medicine News(10 mins):